Oneness Biotech Co., Ltd. (TPEX:4743)

Market Cap	32.98B
Revenue (ttm)	117.93M
Net Income (ttm)	-1.17B
Shares Out	478.03M
EPS (ttm)	-2.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,514,578
Average Volume	2,705,071
Open	69.10
Previous Close	69.00
Day's Range	68.50 - 70.00
52-Week Range	63.10 - 184.00
Beta	1.71
RSI	38.48
Earnings Date	Mar 7, 2025

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan. It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 43
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4743

Financial Performance

In 2024, Oneness Biotech's revenue was 117.93 million, an increase of 35.89% compared to the previous year's 86.78 million. Losses were -1.17 billion, -11.25% less than in 2023.